CALCRL and neoplasm: Similar to knock-down of endothelial Gαs, loss of endothelial CALCRL or blockade of CALCRL by the competitive adrenomedullin receptor antagonist adrenomedullin 22-52 (AM22-52) reduced not only the tumor cell–induced growth of endothelial cells (Fig. 3, b and c) but also tumor cell proliferation in the co-culture model (Fig. 3, d–f).